Results from the SPARE trial: Zytiga alone is as good as Zytiga + ADT

This study provides initial data on mCRPC patients undergoing therapy with Zytiga (abiraterone/prednisone) and suggests that the efficacy may not be compromised if LHRH therapy (such as Lupron or Firmagon) is discontinued. The primary endpoint of this study was radiographic progression-free survival (rPFS) at 1 year and there was no significant difference between the 2 arms.  It was a small study with just 67 patients.  To read the full ASCO Conference summary written by Jason Zhu, MD., Duke University, click here: http://tiny.cc/fs9w7y